This article considers key aspects of the law of patents, trade secrets, copyrights and databases by explaining why they are relevant to the utilization of marine genetic resources (MGRs) 1 (and their intangible informational contents) that are sourced from areas beyond national jurisdiction (ABNJ) in the context of the United Nations Convention on the Law of the Sea (UNCLOS). It also provides an assessment of key lessons learned from global regimes on genetic resources in the food and agriculture and health sectors, with a particular focus on intellectual property (IP) management, benefit sharing and the possible use of standard material transfer agreements. It also explains the legal and policy linkage between the proposal to launch the negotiation of a new international instrument under UNCLOS (inter alia to provide an international framework for the sharing of the benefits arising from MGRs in ABNJ) and the possible establishment of a Global Multilateral Benefit-Sharing Mechanism under the Nagoya Protocol. This article concludes that the appropriate management of intellectual property assets that arise from marine scientific research, including bioprospecting, needs to be considered carefully in the context of promoting research and innovation, and their widest possible dissemination for the advancement of science as a global public good.
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LEGAL AND POLICY BACKGROUND: IP PROTECTION AND MARINE BIOPROSPECTING IN AREAS BEYOND NATIONAL JURISDICTION
The question of the management and protection of intellectual property (IP) assets arising from marine scientific research, including bioprospecting, and of the relationship between intellectual property rights and benefit sharing from utilization of marine genetic resources and their derivates 2 are critically important to designing appropriate regulatory mechanisms to improve the governance framework for marine genetic resources (MGRs) in areas beyond national jurisdiction (ABNJ). In the case of privately funded research as well as university research and public-private partnerships, intellectual property (IP) protection and the appropriate management of IP assets can promote research and innovation as well as their wide dissemination. Patents can provide incentives to promote investments in research and development and -through licensing -potential pathways towards technology transfer, product development and commercialization. However, uncertainties about the legal status of materials, which may arise from the presence of multiple and potentially overlapping patent claims 3 over marine organisms and their separate parts and components may potentially discourage other researchers within the 'technological prospects' covered by such patents. 4 According to the United Nations Convention on the Law of the Sea (UNCLOS), areas beyond national jurisdiction (ABNJ) include both 'the Area', 5 common heritage of mankind, and 'the high seas'. 6 In these oceanic regions which do not fall under the jurisdiction of any State, the exploitation of marine biodiversity is very often unregulated and faces several anthropogenic pressures and threats. 7 At the UN Conference on Sustainable Development ('Rio+20') the international community committed itself 'to address, on an urgent basis, the issue of the conservation and sustainable use of marine biological diversity of areas beyond national jurisdiction, including by taking a decision on the development of an international instrument under [UNCLOS] ' 8 at the 69th session of the UNGA in 2015.
Emerging activities like marine bioprospecting were not envisioned at the time UNCLOS -the overarching legal framework for all human activities in oceans and seas -was drafted. 9 While these activities are currently undertaken in accordance with the principle of 'freedom of scientific research' (under UNCLOS Article 87), the sharing of the benefits arising from the utilization of marine genetic resources is unregulated at the global level and their appropriation occurs on a 'first-come, first-served' basis. In particular, no benefit sharing obligations are established by UNCLOS (or any other international instrument) with regard to the utilization of MGRs taken from ABNJ. Historically, and in light of the access and benefits sharing (ABS) standards now enshrined in the UN Convention on Biological Diversity (CBD) and in its Nagoya Protocol, this situation is perceived as being inequitable and unfair especially for counties with no or limited capacity to undertake oceanographic research and marine bioprospecting.
In order to fill this gap, one of the options under consideration is the development of a new international instrument under UNCLOS that would aim to provide an encompassing framework for the effective conservation and sustainable use of marine biodiversity in ABNJ, including provision on the sharing of the benefits arising from the utilization of marine genetic resources. This proposal has gained attention, most notably within the framework of UN General Assembly and its Ad Hoc Open-ended Informal Working Group to study issues relating to the conservation and sustainable use of marine biological diversity in ABNJ (the UN BBNJ Working Group). 10 The first intersessional workshop, held in New York on 2-3 May 2013, focused precisely on marine genetic resources. The Terms of Reference provided a mandate to consider, inter alia, intellectual property rights issues, and lessons learned from global and regional regimes on genetic resources, experiences and best practices. The present article builds 9. While there is no legal definition of 'bioprospecting', a working definition of this term may be necessary. The Oxford English Dictionary defines bioprospecting as 'the search for plant and animal species from which medicinal drugs and other commercially valuable compounds can be obtained'. See <http://oxforddictionaries.com/definition/english/bioprospecting>. In addition, a study by UNU-IAS highlights that: 'A common distinction is made between scientific research undertaken for noncommercial purpose, also called "pure scientific research", and commerciallyorientated research, also called "applied scientific research". Bioprospecting Intellectual property rights and benefit sharing 173 upon and further expands research previously undertaken as a direct contribution to the work of the UN Working Group on these two topics. 12 
OUTLINE
Issues concerning the protection of MGR-based inventions under patent law are analysed in section 3. Section 4 considers the relationship between patents, trade secrets and the dissemination of information and knowledge arising from marine scientific research, including bioprospecting. While focusing on open access to scientific publications and data, section 5 provides an assessment of selected issues that concern the management of other types of IPRs, namely copyright and proprietary databases, which can play an important role for the generation and dissemination of data, information, knowledge and technologies arising from the utilization of MGRs. It also discusses opportunities and limitations of open source licensing in the field of marine biological innovation. Section 6 provides an assessment of the lessons learned from other global regimes on genetic resources in the food and agriculture and health sectors, by focusing on, inter alia: the relationship between IP protection and benefits sharing; prohibitions and limitations on exclusive right; monitoring and notification requirements; third party transfers; material and information sharing requirements; and the use of material transfer agreements. Section 7 highlights the legal and policy linkages between the proposed option to launch negotiations on a new international instrument under UNCLOS (to provide a framework for the conservation and sustainable use of marine biodiversity in ABNJ, including benefit sharing from MGRs) and the possible establishment of a Global Multilateral Benefit-Sharing Fund under the Nagoya Protocol on ABS. Finally, section 8 provides overarching conclusions and lessons learned from the above analysis.
PATENT-RELATED ISSUES

Patentability of MGR-based inventions
Biomolecules, DNA constructs and marine micro-organisms can be utilized in industrial processes and can be synthesized and replicated in a lab. In addition, they may be modified by human intervention and take on characteristic that do not exist in nature. When such human interventions result in a new biotechnological invention that involves an inventive step and is capable of industrial application, the invention may qualify for patent protection. 14 It provides that a patent shall confer on its owner the right to prevent others from making, using, offering for sale, selling or importing the patented product for a period of 20 years or more. In the case of a process patent, the same rights extend at least to the product obtained directly by the patented process. TRIPs Article 27.1 further requires that '[...] patents be available and patent rights enjoyable without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced'. Its purpose is to protect right-holders against arbitrary policies that may undermine their rights. Thus, States are not allowed to take measures that would discriminate in the granting of patents, for instance because the disclosed invention belongs to a particular technological domain (e.g. marine biotechnology). The question of whether a WTO Member State would be allowed to take measures that exclude the grant of a patent (or the enjoyment of patent rights) for inventions based on MGRs that are taken from areas beyond national jurisdiction (ABNJ) has not yet arisen. However, such a form of limitation is not expressly prohibited under TRIPs, since Article 27.1 does not refer to the origin of the resources used for the invention but rather the place of the invention itself.
Since their inception in the 1980s, biotechnology patents and their effects on research and innovation are controversial. Certain inventions have been purposely excluded from the scope of patentable subject matter as defined by national patent law. This may vary from one country to another. WTO Member States are allowed to not grant patents for plants, animals and, essentially, the biological processes for their production. 15 However, micro-organisms and micro-biological or non-biological processes must be protected. 16 Some countries thus exclude from patentability, inter alia: plants and animals; discoveries of natural substances; and any invention where the prevention of its commercial exploitation is necessary to protect public order, morality or public health. 17 Nonetheless, patent offices in countries with advanced biotechnology capacity have routinely granted patents for gene-based inventions. 18 For instance, in the European Union, 'biological material which is isolated from its natural environment or produced transformed cell lines; proteins; viruses; vectors; methods, technologies and materials for making, using or analysing such materials; and express sequence tags (ESTs by means of technical process may be the subject of an invention even if it previously occurred in nature'. 19 In the United States, three categories of inventions are non-patentable: laws of nature, natural phenomena, and abstract ideas (based on the 'Product of nature doctrine'). 20 The boundaries of such doctrine are routinely tested in disputes that concern the patentability of DNA and its alleged positive or stifling effects on biological innovation. 21 In addition to the United States, Australia, Canada, Indonesia, Japan, Singapore and the 18 Member States of the African Regional ' . In accordance with the patent specification, 'isolated DNA' includes not only complementary DNA and other made-made constructs, but also genomic DNA that has been 'separated from other cellular components which naturally accompany a native human sequence' and 'removed from its naturally occurring environment'. See the Amicus Curiae by the United States Government, which rejects the patentability of DNA, at pp. 7-8, available at: <http://www.genomicslawreport.com/wp-content/ uploads/2010/11/Myriad-Amicus-Brief-US-DOJ.pdf>. The Supreme Court also ordered that the case be re-examined by the Federal Circuit in light of its former unanimous decision in Mayo v Prometheus Laboratories, which held that Prometheus' method claims to a diagnostic test for auto-immune diseases did not meet subject matter patentability standards because the former Intellectual Property Organization generally allow full patentability of animals, plants and biological processes without particular restrictions.
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As regards the implementation of subject matter exclusions, a group of countriesincluding China, India, Malaysia, the Philippines, the Russian Federation, Tunisia, the 16 Member States of the Organisation Africaine de la Propriété Intellectuelle (OAPI), as well as the Member States of the European Patent Organisation (EPO) -provide for a limited subject matter exception that covers plant varieties and/or animal breeds, and essential biological processes. 23 Finally, countries such as those from the Andean Community of Nations, Brazil and Thailand entirely exclude plants, animals (in whole or any part thereof) and essentially biological processes from patentability. . 25 The authors found that a total of 677 claims from the PCT dataset were associated with 8648 sequences belonging to 520 distinct marine species. 26 More recently, Oldham et al. have 'identified 4,162 marine species in patent data of which 1,464 species appear in patent claims'.
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Any comparison of the above studies would be inappropriate due their different methodological assumptions in the selection and assessment of patent data. However, the above figures roughly show that there is a non-negligible number of marine species whose appearance in patent claims suggests their utilization is subject to patent restrictions in various jurisdictions. Intellectual property rights and benefit sharing 177
While patent activities that concern MGRs may be even larger than the above estimates suggest, it is important to recognize that the exact geographical origin of these resources (ie within or beyond national jurisdiction) is often unknown and therefore it is difficult to ascertain what the true extent of patenting activity may be in relation to MGRs from areas beyond the limits of jurisdiction.
28 This is because in most cases the naming of the species of origin of the genetic material used in a biotechnological invention, as well as its geographical origin, is not required by patent law.
Besides, meta-genomics allows determining genes' functions by simply screening a mix of DNA from multiple organisms against a reference library without requiring knowledge of the source organism. 29 The application of molecular genetics and bioinformatics has transformed MGRs into a promising source of appropriable information. The hereditary information which can be found in DNA, coupled with the identification of genes' functions (e.g. the way in which they code for proteins -a process also known as gene expression), can constitute the basis of patent applications that -if granted -provide monopoly rights on the claimed inventions.
The possibility of claiming molecules and DNA constructs previously existing in nature to replicate the processes they perform in nature may impinge on the ability of others to undertaken research on the claimed MGR. 30 Unrestricted or facilitated access to basic information and discoveries as well as research results relating to MGRs may be critical for the advancement of science 31 and by extension for marine scientific research. Thus, the patenting of the results of basic research and, in particular, isolated DNA and bio-molecules that are identical to their natural counterparts, could limit access to materials and research tools. In such cases, patents may impede further innovation. With a view to avoiding this, patent laws normally provide for research exemptions. A research exemption is an exception to the exclusive rights granted by a patent that allows researchers to undertake experiments on the patented invention with a view to discovering unknown effects or making improvements on the invention without the prior consent of the patent-holder. The TRIPs Agreement provides for such exemption. 32 Geo-referencing of sample collection locations appears to be already standard good scientific practice in marine scientific research (MSR) and bioprospecting. However, it is also true that the metadata containing such important information is often fragmented, 34 making it difficult to establish whether a given MGR was collected within a national jurisdiction or in ABNJ. 35 More routine disclosure of the geographical coordinates of collection locations could provide greater legal certainty for all those concerned with research and development. 36 Such information should follow samples of the collected material as well as their sequence data throughout the R&D chain, including specimens held by ex-situ culture collections. This could be done by using a unique identifier number, which should be linked to relevant documentation.
37 Such information should be readily available at any stage of research, development, pre-commercialization and commercialization. This would also promote synergies with the 2010 Nagoya Protocol on ABS, in particular, with the obligation to monitor and enhance transparency about the utilization of genetic resources under Article 17. Relevant information, including information on the 'source' of marine organisms, which may have been collected within or beyond national jurisdiction, could be disclosed at the checkpoint(s) to be established in accordance with the above article.
On the one hand, if disclosed sample collection locations are within areas beyond national jurisdiction, the benefit of geo-referencing would be to exclude the application of domestic access and benefit-sharing legislation or regulatory requirements of any Party to the Nagoya Protocol. On the other hand, in such situations other (multilateral) benefits sharing obligations might be triggered, notably those which may be considered in the context of the BBNJ Working Group.
33. The US jurisprudence has crafted a common law defence in extremely narrow terms in the wake of the leading case, Madey v Duke University, 64 USPQ2d 1727 (Federal Circuit, 2002) . The Court of Appeals for the Federal Circuit held that: 'Regardless of whether a particular institution or entity is engaged in an endeavour for commercial gain, so long as the act is in furtherance of the alleged infringer's legitimate business and is not solely for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry, that act does not qualify for the very narrow and strictly limited experimental use defence. Moreover, the profit or non-profit status of the user is not deter- On the one hand, patent protection may generate tensions with the above Article, because confidentially and non-disclosure of information is required prior to patenting in order to safeguard the novelty of the invention. On the other, patent protection promotes the dissemination of useful technical information (on how to perform the invention) once the patent application (and the disclosure therein) is published. However, nationals in many developing countries have difficulties in benefiting from knowledge on technologies and processes that is disclosed in the patent literature, particularly if such knowledge is only available in the form of publications made by foreign IP offices in foreign languages. 38 The digitization of documents concerning national IP filings and their dissemination through publicly-available databases could enhance access to knowledge, including in the field of marine biological innovation.
Another common assumption is that in jurisdictions where patents are not available for gene-based inventions (because of subject matter exclusions), a more widespread recourse to secrecy and confidentially is relied upon by commercial developers for protecting their innovations compared to jurisdictions where patent protection is available. However, in current commercial practice, patents and trade secrets are used as complementary means of protection that strengthen each other's exclusivity. Patents usually protect the core invention and their disclosure covers only embryonic or early stage research and development results, 'which are insufficient for commercializing the patented technology, absent access to collateral proprietary knowhow'.
39 Such proprietary know-how, which is often developed after the first filing of the patent application, is protectable as a trade secret in accordance with TRIPs Article 39.2. 40 It can also be contractually protected under a confidentiality agreement. 41 The management of IP assets that arise from MSR under a regime of confidentiality or trade secrecy appears to be at odds with the spirit of UNCLOS. This is because UNCLOS Article 244 expressly provides for the publication and dissemination of relevant information and knowledge with a view to promoting openness and transparency of marine science. For example, the Oceanographic Data Exchange Policy of the Intergovernmental Oceanographic Commission (IOC) implements the principles of Article 244 by stating that: 'Member States shall provide timely, free and unrestricted access to all data, associated metadata and products generated under the auspices of IOC programs'. 42 Furthermore, in the context of technology transfer, Article 267 of UNCLOS provides that: 'States, in promoting cooperation pursuant to article 266 [Promotion of the development and transfer of marine technology], shall have due regard for all legitimate interests including, inter alia, the rights and duties of holders, suppliers and recipients of marine technology'. However, this provision is primarily concerned with the transfer of hard (tangible) technologies and only indirectly with the dissemination of data, information and knowledge related to them.
COPYRIGHT-RELATED ISSUES: OPEN ACCESS TO SCIENTIFIC PUBLICATIONS, OPEN-SOURCE LICENSING AND DATABASE PROTECTION
There is an increasing need to raise awareness of the opportunities provided by the copyright system to support new models of distributing information and creative content and thereby helping to bridge the digital divide. 43 Open-access scientific publishing and free and open resources software may contribute to the spread of marine biological innovations and the dissemination of MSR results. Open access to relevant scientific publications, data and software (to analyse this data) could be viewed as an important component of non-monetary benefit-sharing. 44 However, the moderate optimism, which arises from the new opportunities created by open-source business models in scientific publishing, cannot obscure the reality for developing countries, where researchers and users may not have the same access to the Internet, bandwidth and alternate models for managing and distributing information and creative content, as their counterparts in developed countries. 45 The recent push towards open access to research in Europe 46 and in the United States 47 are a promising development, with positive spill-over effects for all those 42 . Resolution IOC-XXII-6 specifies that the term 'Product' shall be understood as 'a valueadded enhancement of data applied to a particular application'. In accordance with UNCLOS Article 249, a limited exception is provided for a coastal State by the Guidelines for the Implementation of Resolution XX-6 of the IOC Assembly Regarding the Deployment of Floats in the High Seas within the Framework of the Argo Programme. Such Guidelines provides that coastal States retain the right to restrict the release of data by the 'Implementer' for a limited period of time if the data is 'of direct significance for the exploration and exploitation of natural resources, whether living or non-living'. This exception to the requirement to make data freely available is designed to protect the rights of the coastal State over their continental shelf and exclusive economic zone (EEZ). Therefore, in no case does it apply to data collected from ABNJ. 49 proposes to make government agencies design and implement a plan to facilitate public access to federally funded research by requiring researchers '[…] to submit a copy of resulting journal articles to the funding agency, which will then make that research widely available within six months'. Other countries such as Brazil, China and South Africa are leading the field in open access implementation in the developing world.
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The journal BioMed Central (BMC) 51 and the Public Library of Science (PLOS ONE -one of the principal cell biology cancer research journals) 52 provide good examples of a business model which was successfully adopted for open-access peerreviewed scientific publishing. In this model, publication fees -including those necessary to cover peer review, editing, journal production, and online hosting and archivingare paid by the authors rather than by readers. In addition, the PLOS Global Participation Initiative pricing programme offers to waive or reduce the payment required of authors from Low and Lower Middle Income Countries with the aim of promoting the widest global participation in open-access publishing. Open-access policies also concern digital data that are owned or produced with the support of public bodies. For instance, the European Commission's Open Data package 53 -in particular, the Commission's updated directive on re-use of public sector information -proposes to make favourable re-use conditions applicable to data held by cultural heritage institutions such as libraries (including university libraries), museums and archives. dissemination of knowledge and data that arise from MSR and marine bioprospecting. Open-source licensing is a form of management of IP assets, initially developed in the software context, whose objective is to disseminate innovation in a non-proprietary fashion. As such, it is an alternative to 'straightforward publication' strategies that would directly place the innovation in the public domain by foregoing IP protection altogether. 55 An open-source approach may be preferable to straightforward publication when: (1) the inventor/developer has automatically vested IP rights in an intellectual asset; or (2) defensive disclosure through publication would still expose the author to the risk that others might seek ownership of the technology; or (3) it is preferable to set terms of use that exclude everyone who does not agree to make improvements available under the same liberal terms that apply to the core technology. 56 In the context or inter-institutional research collaborations and consortium agreements, open-source licensing favours precompetitive collaborations and it is instrumental in 'establishing a robust commons for basic or fundamental technologies whose value is likely to be enhanced by cumulative innovation'.
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In the field of bioinformatics, most enabling technologies are developed under open-source terms. 58 Since 1999, various open-source initiatives have been launched in the life sciences to promote a more transparent, participative, open and inclusive R&D model than there would be in a proprietary setting. For instance, the BIOS CAMBIA's Patent Lens aims at allowing community-developed analytical tools, patent landscapes and decision support software to be created and shared. 59 However, the application of open-source licences to non-software technologies is not something obvious since marine biotechnology, in comparison with software development, is far more technologically diverse and dependent on expensive, time-consuming and complex patents -instead of copyright, which is an automatic and inexpensive form of protection.
Finally, when implementing institutional data-sharing policies, an important IP management issue concerns the appropriate consideration of third parties' IP restrictions that may be carried not only by the data per se, but also by the arrangement of such data (in a database). Dodds et al. explain that a compilation of data or information is copyrightable if they '[…] have been selected, coordinated or arranged in such a way that the resulting work, as a whole, constitutes an original work of authorship'.
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If more authors have contributed to the compilation, the database may be subject to joint copyright ownership. Although the data or information does not need to be new, the way in which it is elected and arranged must show some degree of originality and creativity for the compilation to be protectable under copyright law. In general, copyright protection does not extend to individual data in a database, and such data may be used once extracted from it. This is why a commercial database normally restricts the right to (re)use and further distribute contents extracted from the database by including restrictive clauses in the licensing agreement. Intellectual property rights and benefit sharing 183
Besides copyright protection, the Member States of the European Union are the sole countries that also provide sui generis legal protection for databases. In accordance with the 1996 EU Database Directive, the makers of a database enjoy the right to prevent unauthorized acts of extraction and re-utilization of 'the whole or of a substantial part' of a database content, if it is demonstrated 'that there has been qualitatively and/or quantitatively a substantial investment in either the obtaining, verification or presentation of [such] contents'. 61 Thus, in the case of sui generis rights, there is no requirement for creativity or originality in the way data is selected and arranged, as is the case for copyright. Database protection lasts for 15 years from the date of its creation, with an additional 15 years if substantial changes are made to the content of the database.
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In conclusion, the different sui generis and copyright-related cases reviewed in this section have shown that various centrifugal tendencies within the intellectual property system exercise their influence on policies and practices that are directly relevant to the management of marine scientific research and its outputs. Namely, on the one hand, a tendency towards open access to scientific publications and data, and open-source licensing of marine biological innovations and, on the other, a tendency towards strengthened proprietary rights in the legal protection of databases. How to possibly reconcile these different tendencies and management practices, and their implications for benefit sharing, need to be further considered in the context of international negotiations of an UNCLOS implementing agreement on biodiversity in areas beyond national jurisdiction.
LESSONS LEARNED FROM GLOBAL REGIMES ON GENETIC RESOURCES: THE FOOD AND AGRICULTURE AND HEALTH SECTORS
This section will provide an assessment of the lessons learned from other global regimes on genetic resources in the food and agriculture and health sectors. In order to do this, the key features of the FAO International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA) and the WHO Pandemic Influenza Preparedness Framework for the Sharing of Influenza Viruses and Access to Vaccines and Other Benefits (PIP Framework) will be presented. Their comparative analysis will allow the drawing of key lessons learned on, inter alia: the use of standard material transfer agreements; the relationship between IP protection and benefit sharing; prohibitions and limitations on exclusive rights; monitoring and notification requirements; third party transfers; and material and information-sharing requirements. of crop diversity and the fair and equitable sharing of benefits, in harmony with the CBD. Within biodiversity, the International Treaty defines a subset of genetic resources of particular importance for agriculture and food security -i.e. PGRFA -and it limits its scope of application to them. In this respect, the Treaty can be considered as a lex specialis for crop diversity, whereas the CBD provides the general framework for biodiversity. The International Treaty was created to suit the needs of agriculture and plant breeding. In particular, it establishes a Multilateral System (MLS) of access and benefit sharing (ABS) that consists in pooling selected genetic resources for crops coming from various countries. 63 These pooled resources are available under the facilitated access mechanism of the MLS only if access is required for the purpose of utilization and conservation for research, breeding and training for food and agriculture. This means that national ABS laws that are consonant with the CBD may apply if recipients intend to make use of PGRFA for other purposes, 'such as chemical, pharmaceutical and/or other non-food/feed uses'.
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Materials in the MLS are governed by a set of common rules that States agreed upon in a standard contract called the Standard Material Transfer Agreement (SMTA). Thus, access to PGRFA in the Multilateral System is provided on the basis of the SMTA and hence it does not require ad hoc negotiations between providers and recipients of such materials. This reduces transaction costs as 'access shall be accorded expeditiously, without the need to track individual accessions and free of charge, or, when a fee is charged, it shall not exceed the minimal cost involved'. 65 Providers of PGRFA do not have the obligation to keep track of all subsequent transfers of PGRFA. However, reporting obligations are included in the SMTA in order to ensure that some benefits flow back to the MLS when a product based on MLS materials is commercialized on the market.
The obligation to share benefits is not in favour of a provider, but of the MLS. Thus, the SMTA provides for a 'Third Party Beneficiary' to be able to initiate dispute settlement, should this become necessary, in order to enforce the beneficial interest of the MLS. 66 Through reporting obligations, and in conjunction with the obligation to use the SMTA for any subsequent third-party transfer of PGRFA, the SMTA enables following the chain of transfers between individual providers and recipients of PGRFA at reduced costs.
While the International Treaty encourages facilitating access to all PGRFA, only materials that are under 'the management and control of the Contracting Parties and in the public domain' will be included in the MLS. 67 As regards benefit sharing, it envisages four different tools through which benefits can be shared: the exchange of information; access to and transfer of technology; capacity building; and the sharing of monetary and other benefits from commercialization. 68 In addition, the Treaty emphasizes that facilitated access to the PGRFA itself constitutes a major benefit of the MLS.
69
Under the SMTA, recipients are free to transfer received materials to third parties without the need to seek the providers' prior informed consent (PIC). Compulsory benefit sharing of 1.1 per cent of income from seed sales must be paid to the MLS if 70 the commercialized 'product' incorporates 'the material' received from the MLS, 71 and such 'product' is not freely available for further research and breeding. The latter requirement entails the existence of a patented product (legal restrictions) 72 or restrictions deriving from particular technologies, such as Genetic Use Restriction Technologies (GURT), or certain restrictive licensing practices (contractual restrictions). Thus, the existence of patent rights, which restrict access to a product based on PGRFA from the MLS, is a precondition for the sharing of monetary benefits arising from its commercialization. However, this benefit-sharing trigger -based primarily on (patent-related) access restrictions -has proved to be ineffective, as no companies or individual recipients have ever reported to make benefit-sharing payments under the Treaty.
Since the development of a new plant variety may take more than ten years, the SMTA also envisages an alternative payment scheme, which provides that recipients may voluntarily choose to make immediately crop-based payments at the discounted rate of 0.5 per cent of the overall sales of seeds pertaining to the same crop species obtained from the MLS (without any additional legal triggers). filed a patent application for vaccine developed from a virus strain initially provided by Indonesia to the WHO, without its prior informed consent. This alleged violation of the CBD was reinforced by concerns for developing countries' limited opportunities to obtain the vaccine. These concerns arose not only from the expected effects of the patent, but also from the largely insufficient global production capacity and the conclusion of advance purchase agreements by some developed countries. 75 In response to these criticisms, the World Health Assembly (WHA) decided to develop a novel and fairer virus sharing framework in cases of global pandemic influenza viruses.
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The PIP Framework was eventually adopted in 2011 as a non-legally binding international agreement, 77 which provides for a multilateral benefit-sharing arrangement. 78 Its objective is to improve pandemic influenza preparedness and response, and strengthen the protection against pandemic influenza by strengthening the WHO global influenza surveillance and response system (WHO GISRS), with the objective of a fair, transparent, equitable, efficient and effective system for: (i) the sharing of H5N1 and other influenza viruses with human pandemic potential; and (ii) access to vaccines and sharing of other benefits. 79 However, its scope does not include seasonal influenza viruses or other non-influenza pathogens or biological substances that may be contained in clinical specimens shared under the PIP Framework.
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The PIP Framework envisages the use of two different Standard Material Transfer Agreements (SMTA) for the exchange of virus samples: Besides the SMTA's obligations, industry's direct financial participation in the global influenza preparedness strategy is required by Articles 6.14.3 and 6.14.4 of the PIP Framework, which state that:
Influenza vaccine, diagnostic and pharmaceutical manufactures, using the WHO GISRS, will make an annual partnership contribution to WHO for improving global pandemic influenza preparedness and response.
[…] the annual contribution shall be equivalent to 50% of the running costs of the WHO GISRS 89 [and] will commence in 2012.
The distribution between companies must be based on transparency and equity, and their nature and capacities. Partnership contributions will be used, inter alia, for conducting disease burden studies, strengthening laboratory and surveillance capacity, access and effective deployment of pandemic vaccines and antiviral medicines. An important analogy between a key underpinning of the ITPGRFA -ie the interdependence of states on continuous exchange of plant genetic resources for agricultural usesand a fundamental motivation for improving marine scientific research (MSR) under UNCLOS is the importance of facilitated access to samples and data. However, there are also crucial differences between the two. The MLS covers only 64 species and its monetary benefit-sharing obligations only apply to a single category of 'products' -ie PGRFA sold on the market for direct cultivation or resale. By contrast, the scope of an instrument to further regulate marine scientific research in ABNJ could apply to all marine biodiversity in such areas, which encompasses potentially millions of species. The products and processes issued from such research may be extremely heterogeneous and encompass applications across multiple technological domains. Thus, the administration of a large number of transactions through an SMTA-like mechanism for MGRs in ABNJ could prove overwhelmingly burdensome. There is also a trade-off between the possible standardization of benefit-sharing obligations and their triggers in order to reduce transaction costs, and the need to accommodate heterogeneous types of products, processes, applications and benefits derived from MGRs in various sectors. The WHO PIP Framework is also characterized by a narrow scope of application and targets a homogenous set of applications in the field of influenza vaccine -diagnostic and pharmaceutical production. Furthermore, it relies on the WHO Global Influenza Surveillance and Response System, which includes an elaborated research infrastructure with a clear global public health mandate and a structured policy framework for international cooperation. This has also allowed a differentiation between the rights, duties and obligations of public research institutes (regulated under SMTA 1) and those of other for-profit research entities (regulated under SMTA 2). These peculiar characteristics have made possible the direct contribution and involvement of relevant companies and other stakeholders in the WHO global influenza preparedness strategy, including the negotiation and acceptance of benefit-sharing options. An important lesson to be learned is that the marine scientific research community, including marine biotechnology companies and the private sector, should play a proactive role in future discussions concerning MGRs and benefit sharing at the UN Working Group on BBNJ. 92 Finally, this comparative analysis suggests considering the following elements as part of the available regulatory options for marine scientific research and benefit sharing from MGRs in ABNJ:
• the need to envisage material and information sharing requirements as a fundamental form of non-monetary benefit sharing; • the relationship between intellectual property rights and benefits sharing as a trigger of users' obligations, including royalty and/or milestone-type payments to a multilateral fund; • the possible introduction of prohibitions and limitations on obtaining exclusive rights on MGRs from ABNJ (in general or under specific circumstances) in accordance with UNCLOS Article 241; • the potential use of standard material transfer agreements;
• the regulation of third party transfers, including an obligation to pass on to any subsequent recipient benefit-sharing obligations; • monitoring mechanisms, notification requirements and dispute settlement procedures and mechanisms; • the possible role of third party beneficiary's rights, including the right to act on behalf and in the interest of the international community in the context of dispute settlement; • the possible role of partnership contributions for commercial partners interested in accessing materials and metadata from institutions that belong to public MGR research networks.
THE RELATIONSHIP BETWEEN UNCLOS NEGOTIATIONS AND A GLOBAL MULTILATERAL BENEFIT-SHARING MECHANISM UNDER THE NAGOYA PROTOCOL
The Nagoya Protocol as such only applies to genetic resources within national jurisdictions. In particular, it was explained elsewhere that:
93
Both UNCLOS and the CBD provide the legal framework for activities related to marine genetic resources from organisms found within national sovereignty (i.e. in the internal waters, 94 archipelagic waters 95 and the territorial sea 96 ) or jurisdiction (i.e. the exclusive economic zone 97 and the continental shelf 98 ). However, divergent views continue to be held regarding the applicability of the CBD to marine genetic resources from areas beyond national jurisdiction. As regards the components of biological diversity, the CBD's scope is set out in Article 4(a), which limits its application to areas within the limits of national jurisdiction. However, […] the CBD is also applicable to activities related to biological resources that are sourced from areas beyond national jurisdiction by virtue of Article 4(b). The latter provides that the CBD applies, in the case of processes and activities, regardless of where their effects occur, carried out under 93. Vierros et al., supra n 28. Footnotes n 94 to 99 were included in the original text. 94. The internal waters are the waters situated on the landward side of the baselines (UNCLOS, Article 8). A baseline is a line from which the seaward limits of maritime zones are measured. 95. The archipelagic waters are the waters enclosed by the archipelagic baselines (UNCLOS, Article 49). 96. The breadth of the territorial sea extends up to a limit not exceeding 12 nautical miles, measured from the baselines (UNCLOS, Article 3). 97. The EEZ lies beyond and adjacent to the territorial sea up to 200 miles from the baselines (UNCLOS, Articles 55 and 57). 98. The continental shelf comprises the seabed and subsoil that extend beyond the territorial sea throughout the natural prolongation of its land territory to the outer edge of the continental margin, or to a distance of 200 nautical miles from the baselines where the outer edge of the continental margin does not extend up to that distance (UNCLOS, Article 76).
